Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel CD8 Treg Network Modulator for Treatment of Autoimmune Disease, at FOCIS 2023 Annual Meeting

Mozart Therapeutics presented preclinical data for MTX-101, a novel CD8 Treg network modulator for the treatment of autoimmune disease, at FOCIS 2023 Annual Meeting. The findings suggest that MTX-101 is well-tolerated in humanized mice and selectively acts on CD8 Treg in blood and tissues without activating other immune cells or increasing pro-inflammatory cytokines. MTX-101 possesses a favorabl..